Neola Medical Receives FDA Breakthrough Device Designation

Neola Medical AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Neola®, the Company’s medical device for non-invasive, continuous lung monitoring in preterm born babies, with the...

Neola Medical invites to presentation of the Q2 report 2026

Neola Medical AB (publ) invites investors, analysts and journalists to a live presentation of the Company’s Q2 report 2026 on Thursday, August 20, 2026, at 11:00 CEST. The presentation will be held online and hosted by Investor Studios. The Q2 report will be...

Neola Medical offentliggör utfall i företrädesemissionen

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, HONG KONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS, ELLER I NÅGON ANNAN JURISDIKTION...